Fda new drug approvals 2018

The FDA approved 59 new drugs in 2018, including treatments for various diseases and conditions such as cancer, rare genetic disorders, and infectious diseases. Here are some of the notable new drug approvals in 2018:

  1. Brexafemme (ibrexafungerp): An oral antifungal medication for the treatment of vulvovaginal yeast infections caused by Candida species.
  2. Zynquista (sotagliflozin): An oral medication for the treatment of type 1 diabetes.
  3. Orilissa (elagolix): An oral medication for the treatment of endometriosis-related pain.
  4. Kymriah (tisagenlecleucel): A CAR-T cell therapy for the treatment of certain types of blood cancer, including acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).
  5. Yescarta (axicabtagene ciloleucel): A CAR-T cell therapy for the treatment of certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL).
  6. Breyanzi (lisocabtagene vicleucel): A CAR-T cell therapy for the treatment of certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
  7. Gazyva (obinutuzumab): A CD20-targeted antibody for the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).
  8. Venclexta (venetoclax): An oral medication for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
  9. Imfinzi (durvalumab): A PD-L1 inhibitor for the treatment of non-small cell lung cancer (NSCLC) and urothelial carcinoma.
  10. Lutathera (lutetium Lu 177 dotatate): A radiolabeled somatostatin analog for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
  11. Apretude (cabotegravir): An injectable HIV-1 integrase strand transfer inhibitor for the treatment of HIV-1 infection.
  12. Cabenuva (cabotegravir and rilpivirine): An oral and injectable HIV-1 integrase strand transfer inhibitor for the treatment of HIV-1 infection.
  13. Zepzelca (lurbinectedin): An oral medication for the treatment of small cell lung cancer (SCLC).
  14. Pomalyst (pomalidomide): An oral medication for the treatment of multiple myeloma.
  15. Xtandi (enzalutamide): An oral medication for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

These are just a few examples of the many new drugs approved by the FDA in 2018. You can find the complete list of new drug approvals on the FDA's website.